NDATRANSDERMALGEL
Approved
Jun 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
DIVIGEL (estradiol) by Convert Pharmaceuticals is estrogen receptor agonists [moa]. Approved for menopause, postmenopausal vaginal atrophy, atrophic vaginitis and 1 more indications. First approved in 2007.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIVIGEL is a transdermal estradiol gel approved in 2007 for hormone replacement therapy and treatment of menopause-related conditions. It works as an estrogen receptor agonist to restore hormone levels in postmenopausal and hypogonadal patients. The product addresses 20+ indications spanning menopausal syndrome, vaginal atrophy, cardiovascular disease prevention, and off-label psychiatric and metabolic uses.
$1MPart D
LOE ApproachingDeclining
As lifecycle approaches LOE, brand team is transitioning from growth operations to managed decline and generic transition planning with reduced headcount expectations.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications (4)
Worked on DIVIGEL at Convert Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.